Affiliated with uOttawa

REaCT
REthinking Clinical Trials

REaCT: REthinking Clinical Trials

REaCT-G

Survey:

  • Hilton J, Vandermeer L, Sienkiewicz M, Mazzarello S, Hutton B, Stober C, Fergusson D, Blanchette P, Joy AA, Brianne Bota A, Clemons M. Filgrastim use in patients receiving chemotherapy for early-stage breast cancer-a survey of physicians and patients. Support Care Cancer. 2018 Feb 6. doi: 10.1007/s00520-018-4074-8. [Epub ahead of print] PubMed PMID: 29411131.

Clinical Trial Feasibility:

  • Ibrahim MFK, Hilton J, Mazzarello S, Fergusson D, Hutton B, Robinson A, Califaretti N, Hsu T, Gertler S, Mates M, Stober C, Vandermeer L, Mallick R, Clemons M. A multi-center pragmatic, randomized, feasibility trial comparing standard of care schedules of filgrastim administration for primary febrile neutropenia prophylaxis in early-stage breast cancer. Breast Cancer Res Treat. 2017 Dec 6. doi: 10.1007/s10549-017-4604-y. [Epub ahead of print] PubMed PMID: 29214415.

Systematic Review:

  • Fernandes R, Majeed H, Hutton B & Clemons M et al. Optimal type, duration and timing of granulocyte colony stimulating factor (GCSF) for primary febrile neutropenia prophylaxis in patients receiving chemotherapy for early stage breast cancer – a systematic review. J Glob Oncol.2018 Sep;4:1-8. doi: 10.1200/JGO.2016.008540. Epub 2017 Apr 21.

Systematic Review:

  • Fernandes R, Majeed H, Hutton B & Clemons M et al. Optimal type, duration and timing of granulocyte colony stimulating factor (GCSF) for primary febrile neutropenia prophylaxis in patients receiving chemotherapy for early stage breast cancer – a systematic review. J Glob Oncol.2018 Sep;4:1-8. doi: 10.1200/JGO.2016.008540. Epub 2017 Apr 21.

Trial Results:

  • Clemons M, Fergusson D, Simos D, Mates M, Robinson A, Califaretti N, Zibdawi L, Bahl M, Raphael J, Ibrahim MFK, Fernandes R, Pitre L, Aseyev O, Stober C, Vandermeer L, Saunders D, Hutton B, Mallick R, Awan AA, Hilton J. A multi-centre, randomised trial comparing schedules of G-CSF (filgrastim) administration for primary prophylaxis of chemotherapy-induced febrile neutropenia in early stage breast cancer.  Ann Oncol 2020 Apr 20; S0923-7534(20)39296-6. doi: 10.1016/j.annonc.2020.04.005.

REaCT-TC

  • Fernandes R, Mazzarello S, Stober C, Vandermeer L, Dudani S, Ibrahim MF, Majeed H, Perdrizet K, Shorr R, Hutton B, Fergusson D, Clemons M. Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review. Breast Cancer Res Treat. 2017 Jan;161(1):1-10. doi: 10.1007/s10549-016-4028-0. Epub 2016 Oct 25. Review. PubMed PMID: 27783280.
  • Clemons, M, Fergusson D, Joy AA, Meza-Junco J, Price Hiller J, Mackey J, Ng T, Zhu X, Ibrahim MFK, Sienkiewicz M, Saunders D, Vandermeer L, Pond G, Basulaiman B, Awan A, Pitre L, Nixon NA, Hutton , Hilton J, A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia. Submitted to British Cancer Journal

REaCT-TC

  • Fernandes R, Mazzarello S, Stober C, Vandermeer L, Dudani S, Ibrahim MF, Majeed H, Perdrizet K, Shorr R, Hutton B, Fergusson D, Clemons M. Optimal primary febrile neutropenia prophylaxis for patients receiving docetaxel-cyclophosphamide chemotherapy for breast cancer: a systematic review. Breast Cancer Res Treat. 2017 Jan;161(1):1-10. doi: 10.1007/s10549-016-4028-0. Epub 2016 Oct 25. Review. PubMed PMID: 27783280.
  • Clemons, M, Fergusson D, Joy AA, Meza-Junco J, Price Hiller J, Mackey J, Ng T, Zhu X, Ibrahim MFK, Sienkiewicz M, Saunders D, Vandermeer L, Pond G, Basulaiman B, Awan A, Pitre L, Nixon NA, Hutton , Hilton J, A multi-centre study comparing granulocyte-colony stimulating factors to antibiotics for primary prophylaxis of docetaxel-cyclophosphamide induced febrile neutropenia. Submitted to British Cancer Journal

REaCT-BTA and de-escalation of BMAs

  • Hutton B, Mazzarello S, Clemons M. Dosing Strategies of Bone-Targeting Agents. JAMA Intern 2015 Nov;175(11):1864-5. doi: 10.1001/jamainternmed.2015.4789. PubMed PMID: 26524744.
  • Ibrahim MF, Mazzarello S, Shorr R, Vandermeer L, Jacobs C, Hilton J, Hutton B, Clemons M. Should de-escalation of bone-targeting agents be standard of care for patients with bone metastases from breast cancer? A systematic review and meta-analysis. Ann Oncol. 2015 Nov;26(11):2205-13. doi: 10.1093/annonc/mdv284. Epub 2015 Jun 28. Review. PubMed PMID: 26122727.
  • Hutton B, Addison CL, Clemons M. The ZOOM trial: more boon than doom? Lancet Oncol. 2013 Sep;14(10):e387-8. doi: 10.1016/S1470-2045(13)70297-3. PubMed PMID: 23993380.
  • Hutton B, Morretto P, Emmenegger U, Mazzarello S, Kuchuk I, Addison CL, Crawley F, Canil C, Malone S, Berry S, Fergusson D, Clemons M. Bone-targeted agent use for bone metastases from breast cancer and prostate cancer: A patient survey. J Bone Oncol. 2013 Jun 21;2(3):105-9. doi: 10.1016/j.jbo.2013.05.002. eCollection 2013 Sep. PubMed PMID: 26909279; PubMed Central PMCID: PMC4723402.
  • Hutton B, Addison C, Mazzarello S, Joy AA, Bouganim N, Fergusson D, Clemons M. De-escalated administration of bone-targeted agents in patients with breast and prostate cancer-A survey of Canadian oncologists. J Bone Oncol. 2013 Apr 15;2(2):77-83. doi: 10.1016/j.jbo.2013.03.001.
  • Clemons M, Ong M, Stober, C, Ernst S, Booth C, Canil C, Mates M, Roberson A, Blanchette P, Joy AA, Hilton J, Aseyev O, Pond G, Jeong A, Hutton B, Mazzarello S, Vandermeer L, Kushnir I, Fergusson D. A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. ASCO 2019 Abstract 11501
  • Awan AA, Hutton B, Hilton J, Mazzarello S, Van Poznak C, Vandermeer L, Bota B, Stober C, Sienkiewicz M, Fergusson D, Shorr R, Clemons M. De-escalation of bone-modifying agents in patients with bone metastases from breast cancer: a systematic review and meta-analysis. Breast Cancer Res Treat. 2019 Aug;176(3):507-517. doi: 10.1007/s10549-019-05265-1. Epub 2019 May 11.PMID: 31079283
  • Ng TL, Tu MM, Ibrahim MFK, Basulaiman B, McGee SF, Srikanthan A, Fernandes R, Vandermeer L, Stober C, Sienkiewicz M, Jeong A, Saunders D, Awan AA, Hutton B, Clemons MJ. Long-term impact of bone-modifying agents for the treatment of bone metastases: a systematic review. Support Care Cancer. 2020 Jun 13. doi: 10.1007/s00520-020-05556-0. Online ahead of print.PMID: 32535678
  • Clemons M, Ong M, Stober, C, Ernst S, Booth C, Canil C, Mates M, Roberson A, Blanchette P, Joy AA, Hilton J, Aseyev O, Pond G, Jeong A, Hutton B, Mazzarello S, Vandermeer L, Kushnir I, Fergusson D. A randomised trial of 4- versus 12-weekly administration of bone-targeted agents in patients with bone metastases from breast or castration-resistant prostate cancer. accepted Eur J of Cancer.

REaCT-Dex

  • Jacobs C, Hutton B, Mazzarello S, Smith S, Joy A, Amir E, Ibrahim MF, Gregario N, Daigle K, Eggert L, Clemons M. Optimisation of steroid prophylaxis schedules in breast cancer patients receiving docetaxel chemotherapy-a survey of health care providers and patients. Support Care Cancer. 2015 Nov;23(11):3269-75. doi: 10.1007/s00520-015-2731-8. Epub 2015 May 3. PubMed PMID: 25933700.
  • Hsu T, Fergusson D, Stober C, Daigle K, Moledina N, Vandermeer L, Pond G, Hilton J, Hutton B, M Clemons. A randomised clinical trial comparing physician-directed or fixed-dose steroid replacement strategies for incomplete dexamethasone dosing prior to docetaxel chemotherapy. Submitted Supportive Care in Cancer.

REaCT-TNBC

  • Jacobs C, Clemons M, Mazzarello S, Hutton B, Joy AA, Brackstone M, Freedman O, Vandermeer L, Ibrahim M, Fergusson D, Hilton J. Enhancing accrual to chemotherapy trials for patients with early stage triple-negative breast cancer: a survey of physicians and patients. Support Care Cancer. 2017 Jun;25(6):1881-1886. doi: 10.1007/s00520-017-3580-4. Epub 2017 Jan 27. PubMed PMID: 28127659.

REaCT-TAPS

  • Fernandes R, Mazzarello S, Hutton B, Shorr R, Majeed H, Ibrahim MF, Jacobs C, Ong M, Clemons M. Taxane acute pain syndrome (TAPS) in patients receiving taxane-based chemotherapy for breast cancer-a systematic review. Support Care Cancer. 2016 Aug;24(8):3633-50. doi: 10.1007/s00520-016-3256-5. Epub 2016 May 5. Review. PubMed PMID: 27146496.
  • Fernandes R, Mazzarello S, Majeed H, Smith S, Shorr R, Hutton B, Ibrahim MF, Jacobs C, Ong M, Clemons M. Treatment of taxane acute pain syndrome (TAPS) in cancer patients receiving taxane-based chemotherapy-a systematic review. Support Care Cancer. 2016 Apr;24(4):1583-94. doi: 10.1007/s00520-015-2941-0. Epub 2015 Sep 19. Review. PubMed PMID: 26386706.
  • Fernandes R, Mazzarello S, Hutton B, Shorr R, Ibrahim MF, Jacobs C, Ong M, Clemons M. A Systematic Review of the Incidence and Risk Factors for Taxane Acute Pain Syndrome in Patients Receiving Taxane-Based Chemotherapy for Prostate Cancer. Clin Genitourin Cancer. 2017 Feb;15(1):1-6. doi: 10.1016/j.clgc.2016.07.018. Epub 2016 Jul 28. Review. PubMed PMID: 27554586.

REaCT VA

  • LeVasseur, N, Stober, C, Daigle, K, Robinson, A, McDiarmid, S, Mazzarello, S Hutton, B, Joy, AA, Fergusson, D, Hilton, J, McInnes, M, Clemons, M. Optimising vascular access for patients receiving intravenous systemic therapy for early stage breast cancer – A survey of oncology nurses and physicians. Curr Oncol. 2018 Aug;25(4):e298-e304. doi: 10.3747/co.25.3903. Epub 2018 Aug 14.
  • LeVasseur, N, Stober, C, Ibrahim, M, Gertler S, Hilton, J, Robinson, A, McDiarmid, S,Fergusson, D, Mazzarello, S, Hutton, B, Joy, AA, McInnes, M, Clemons, M. Perceptions around vascular access for intravenous systemic therapy and risk factors for lymphedema in early stage breast cancer – A patient survey. Curr Oncol.2018 Aug;25(4):e305-e310. doi: 10.3747/co.25.3911. Epub 2018 Aug 14.
  • Robinson, A, Souied, O, Bota, AB, Levasseur, N, Stober, N, Hilton, J, Kamel, D, Hutton, B, Vandermeer, L, Mazzarello, S, Joy, AA, Fergusson, D, McDiarmid, S, McInnes, M, Shorr, R, Clemons, M. Optimal vascular access strategies for patients receiving chemotherapy for early stage breast cancer: a systematic review. Breast Cancer Res2018 Oct;171(3):607-620. doi: 10.1007/s10549-018-4868-x. Epub 2018 Jul 4.
  • Clemons M, Stober C, Kehoe A, Bedard D, MacDonald F, Brunet MC, Saunders D, Vandermeer L, Mazzarello S, Awan A, Basulaiman B, Robinson A, Mallick R, Hutton B, Fergusson D. A randomized trial comparing vascular strategies for patients receiving chemotherapy trastuzumab for early-stage breast cancer.  Support Care Cancer. 2020 Jan 30. doi: 10.1007/s00520-020-05326-y. [Epub ahead of print] PMID: 32002617
  • Robinson A, Stober C, Fergusson D, Kehoe A, Bedard D, MacDonald F, Brunet MC, Saunders D, Mazzarello S, Vandermeer L, Joy AA, Awan A, Basulaiman B, Mallick R, Hutton B, Clemons M; REaCT investigators. A multicentre, randomized pilot trial comparing vascular access strategies for early stage breast cancer patients receiving non-trastuzumab containing chemotherapy. Breast Cancer Res Treat. 2019 Nov;178(2):337-345. doi: 10.1007/s10549-019-05388-5. Epub 2019 Aug 7.  PMID: 31392518

REaCT-ADM

  • Arnaout A, Zhang J, Frank S, Momtaz M, Cordeiro E, Roberts R, Ghumman A, Fergusson D, Stober C, Pond G, Jeong A, Vandermeer L, Hutton B, Clemons M. A randomised controlled trial comparing Alloderm-RTU with DermACELL in immediate subpectoral implant-based breast reconstruction.  Submitted to JPRAS.

REaCT-ADM

  • Robertson SJ, Ibrahim MFK, Stober C, Hilton J, Kos Z, Mazzarello S, Ramsay T, Fergusson D, Vandermeer L, Mallick R, Arnaout A, Dent SF, Segal R, Sehdev S, Gertler S, Hutton B, Clemons M. Does integration of Magee equations into routine clinical practice affect whether oncologists order the Oncotype DX test? A prospective randomized trial. J Eval Clin Pract. 2019 Apr;25(2):196-204. doi: 10.1111/jep.13094. Epub 2019 Jan 23. PMID: 30672056
  • de Lima MAG, Clemons M, Van Katwyk S, Stober C, Robertson SJ, Vandermeer L, Fergusson D, Thavorn K. Cost analysis of using Magee scores as a surrogate of Oncotype DX for adjuvant treatment decisions in women with early breast cancer. J Eval Clin Pract. 2019 Jul 9. doi: 10.1111/jep.13223. [Epub ahead of print]. PMID: 31287198
  • Robertson SJ, Pond GR, Hilton J, Petkiewicz SL, Ayroud Y, Kos Z, Gravel DH, Stober C, Vandermeer L, Arnaout A, Clemons M. Selecting Patients for Oncotype DX Testing Using Standard Clinicopathologic Information. Clin Breast Cancer. 2020 Feb;20(1):61-67. doi: 10.1016/j.clbc.2019.07.006. Epub 2019 Aug 22. PMID: 31551182